Espindolol

Research use only, not for human use.

Espindolol is a novel non-selective β blocker with central 5-HT1a and partial β2 receptor agonist effects.

Espindolol is a novel non-selective β blocker with central 5-HT1a and partial β2 receptor agonist effects.(In Vivo):Placebo-treated rats progressively lost body weight (-15.5 ± 7.2 g), lean mass (-1.5 ± 4.2 g), and fat mass (-15.6 ± 2.7 g), while espindolol treatment increased body weight (+8.0 ± 6.1 g, p < 0.05), particularly lean mass (+43.4 ± 3.5 g, p < 0.001), and reduced fat mass further (-38.6 ± 3.4 g, p < 0.001). Anabolic/catabolic signaling was assessed in gastrocnemius muscle. Espindolol decreased proteasome and caspase-3 proteolytic activities by approximately 50 % (all p < 0.05).

——

Animal Model:Male Sprague Dawley ratsDosage:15 mg/kg Administration:Intraperitoneal injection; 15 mg/kg, 20 min acute treatment or 24 h, 16 h and 20 min short-term treatment before [3H]-WAY 100635 injection Result:Reduced [3H]-WAY 100635 accumulation in 5-HT1A receptor-containing brain areas, but showed no effect on the dorsal raphe nucleus (DRN), and the CA1 and CA3 hippocampal areas.

AGI-001 | MT-102 | AGI001 | MT102 | AGI 001 | MT 102

Endocrinology/Hormones

5-HT Receptor

——

——

——

26328-11-0

248.326

C14H20N2O2

>98% (HPLC)

In Vitro:?DMSO : 100 mg/mL (402.71 mM)

CC(C)NC[C@H](O)COc1cccc2[nH]ccc12

——

(-20℃)

With Ice Pack

≥ 2 years